Views & Analysis Creating headroom: can cutting spend on low-value prescripti... Can reducing NHS spending on 'low-value' prescriptions help fund new drugs?
Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Views & Analysis Budget impact and cost effectiveness: Can the UK learn from ... Leela Barham examines the approach of the Institute for Clinical and Economic Review.
Views & Analysis The budget impact of new medicines What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
News GSK sets up Nucala and Dupixent showdown in COPD GSK has said new data leads it to believe Nucala will be "highly competitive" with rival biologic Dupixent in COPD - if it gets approved by the FDA.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
